BGMS — Bio Green Med Solution Share News
0.000.00%
Last trade - 00:00- $5.02m
- $1.68m
- $0.75m
NASDAQ RESUMED AT 03:39 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:34 PM
Brief: Cyclacel Pharmaceuticals announces $3 million private placement offering of convertible preferred stock
Brief: Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Cyclacel Pharmaceuticals Announces Stock Split
Brief: Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results And Provides Business Update
Brief: Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering Of Convertible Preferred Stock
Brief: Cyclacel Pharmaceuticals Says Datuk Dr.Doris Wong Sing Ee Elected As CEO & Executive Director
Brief: Cyclacel Pharmaceuticals Announces Creditors Voluntary Liquidation Of UK Subsidiary
Brief: Cyclacel Pharma Announces Agreement For The Acquisition Of Preferred Stock By David Lazar
Brief: Cyclacel Pharmaceuticals Announces Its Exploration Of Potential Strategic Alternatives
Cyclacel Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Cyclacel Q3 Net Income USD -1.957 Million
Cyclacel Pharmaceuticals Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Cyclacel Pharmaceuticals Reports New Clinical Data From Ongoing, Phase 2 Study Of Oral Fadraciclib At The 2024 Eortc-Nci-Aacr Symposium
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cyclacel Q2 Net Income USD -3.257 Million
Cyclacel Pharmaceuticals Inc expected to post a loss of $1.43 a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of $1.43 a share - Earnings Preview